CN106822986A - A kind of preparation method of the porous ball hemostatic material of shitosan agar oligosaccharide - Google Patents
A kind of preparation method of the porous ball hemostatic material of shitosan agar oligosaccharide Download PDFInfo
- Publication number
- CN106822986A CN106822986A CN201710224056.9A CN201710224056A CN106822986A CN 106822986 A CN106822986 A CN 106822986A CN 201710224056 A CN201710224056 A CN 201710224056A CN 106822986 A CN106822986 A CN 106822986A
- Authority
- CN
- China
- Prior art keywords
- shitosan
- agar oligosaccharide
- hemostatic material
- solution
- ball
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of porous ball hemostatic material preparation method of shitosan agar oligosaccharide.Methods described prepares shitosan agar oligosaccharide composite solution including S1.；S2. by crosslinking agent 1,3 diglycidyl ether glycerine are added in compound alcoholic solution, under conditions of 130 ~ 150W of ultrasonic power, shitosan agar oligosaccharide composite solution is added drop-wise to and contains 1, in the compound alcoholic solution of 3 diglycidyl ether glycerine, completion of dropping stops ultrasound, and 600 ~ 800rpm is stirred 30 minutes；S3. ball is filtered out, is washed, freeze-drying is obtained final product.Hemostatic material good biocompatibility prepared by the present invention, safety non-toxic；Blood clotting can rapidly be facilitated, with efficient styptic activity；With certain volume, it is not easily accessible blood and causes thrombotic risk.Meanwhile, possess excellent wound adaptability, it is particularly well-suited to deep, narrow and irregular wound hemostasis.Preparation process is simple of the present invention, it is easy to industrialized production.
Description
Technical field
The invention belongs to biomedical materials field, more particularly to a kind of porous ball of shitosan-agar oligosaccharide stops
The preparation method of blood material.
Background technology
In the wartime, more than 80% injures and deaths are to lose life because wound is lost blood；Time of peace, because of natural calamity, thing
Therefore the massive blood loss that the wound that causes of the accident such as disaster causes is also disability, main causes of death.Traditional hemostatic cotton
Yarn, bandage etc. are very undesirable for the haemostatic effect of the wound such as irregular shape, deep, narrow, arteriorrhexis；Although styptic powder has
Excellent wound applicability, but easily flow to form thrombus into blood obstruction distal aorta.Therefore need a kind of suitable for scene
With clinical emergency treatment, quick, safe and efficient hemostatic material replaces traditional hemostatic material.
Shitosan is a kind of natural biological polysaccharide of generation after chitin deacetylase, is so far that the unique alkalescence of nature is more
Sugar, its natural resources very abundant.Due to being acted on excellent biocompatibility, broad spectrum antibacterial, hemostasis wound healing promoting,
And biodegradable safety non-toxic, it is widely used in the fields such as medicine, food, bioengineering.Agar-agar is by red algae such as parmelia saxatilis
The marine polysaccharide of the extractions such as dish, seaweed, fragrant plant mentioned in ancient texts, be by C1,3 connection β-D- galactolipins and C1,4 connection 3,6- inner ethers-α-
The chain neutral sugar that L- galactose residues are alternately connected.Used as a kind of polysaccharide, agar-agar viscosity is high, water-soluble low, is difficult to be absorbed,
Therefore it is very limited in application aspect.But the agar oligosaccharide obtained by degraded, good water solubility is conducive to human body to inhale
Receive, not only the general characteristic with functional oligose, also with stronger anticancer, anti-oxidant, anti-inflammatory, moisture absorption isoreactivity, and
Have no toxic side effect, have broad application prospects.
In hemostatic material product, food and medicine Surveillance Authority of the U.S. in 2002（FDA）Have approved a kind of chitosan-based
External application HemCon tourniquet bandages, and applied in Iraq and Afghan battlefield, imitated in the application of the hyporrhea surface of a wound
Fruit significantly, but usually influences actual effect when arterial hamorrhage is stopped blooding because layman's operation is difficult to find blutpunkte accurately, no
Suitable for the hemostasis of the wound such as severe haemorrhage, particularly irregular shape, deep, narrow, arteriorrhexis.With in 2002,
QuikClot Zeolite hemostatics powder ratifies the first aid for severe haemorrhage wound, but QuikClot styptic powders in use by FDA
There is exothermic reaction can cause wound tissue to injure more than 100 DEG C of defects of high temperature.Powdered hemostatic material is easy in vascular
Inner chamber remains, and obstruction distal aorta flows to form thrombus.WoundStat styptics obtained U.S. FDA accreditation in 2008 simultaneously
Army is widely used in the same year, but found there is the risk for causing tip thrombus into blood circulation system later, based on life
Thing security consideration, U.S. army has announced to forbid to use WoundStat forever for 2009.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of that prior art is present, there is provided while a kind of energy quick-acting haemostatic powder, have both good
Good biology and histocompatbility, and solve the shitosan-agar oligosaccharide of the bio-safety hidden danger that the easy lower tape of particulate matter comes
The preparation method of porous ball hemostatic material.
Above-mentioned purpose of the invention is achieved by the following technical programs：
A kind of preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. 2% ~ 3% is prepared respectively（W/V）Chitosan solution and 0.5% ~ 1.5%（W/V）The agar oligosaccharide aqueous solution, the shell gathers
Sugar juice solvent is 1%-3%（V/V）Aqueous acetic acid；Take isometric chitosan solution and the agar oligosaccharide aqueous solution is mixed, system
Obtain shitosan-agar oligosaccharide composite solution；
S2. it is 4 1,3- diglycidyl ether glycerine to be added into volume ratio:In the compound alcoholic solution of 6 isopropanol/isooctanol, 1,
3- diglycidyl ethers glycerine content in the compound alcoholic solution of isopropanol/isooctanol is 0.5% ~ 2%（V/V）, in ultrasonic power 130
Under conditions of ~ 150W, above-mentioned shitosan-agar oligosaccharide composite solution is added drop-wise to and contains 1,3- diglycidyl ether glycerine
In the compound alcoholic solution of isopropanol/isooctanol, wherein, shitosan-agar oligosaccharide composite solution and contain 1,3- diglycidyls
The volume ratio of the compound alcoholic solution of the isopropanol/isooctanol of ether glycerine is 1:4 ~ 6, completion of dropping stops ultrasound, and 600 ~ 800rpm is stirred
Mix 30 minutes to obtain ball；
S3. the porous ball hemostatic material of shitosan-agar oligosaccharide is obtained final product after filtering out ball through washing, pre-freeze, freeze-drying.
Preparation method of the present invention is combined alcoholic solution by from isopropanol/isooctanol, and adds 1,3- diglycidyl ethers
Glycerine as porous ball hemostatic material porosity prepared by crosslinking agent and shitosan-agar oligosaccharide composite solution reaction it is big,
Swelling effect is excellent, can quick water absorption and swelling, block the surface of a wound, blood clotting is facilitated rapidly, with efficient styptic activity；And preparation is more
Hole ball hemostatic material has certain volume, is not easily accessible blood and causes thrombotic risk.
Preferably, washing described in S3 refer to successively washed with the ethanol that volumetric concentration is 100% and 50% respectively ball 3 times with
On.
The porous ball hemostatic material of shitosan-agar oligosaccharide prepared using the above method, it is characterised in that institute
The particle diameter of the porous ball hemostatic material drying regime of shitosan-agar oligosaccharide is stated for 0.5 ~ 2 mm, porosity is 55% ~ 90%,
Swelling rear particle diameter is 4 ~ 8 mm.
Preferably, the particle diameter of the porous ball hemostatic material drying regime of the shitosan-agar oligosaccharide is 1.4 ~ 2 mm,
Porosity is 83% ~ 90%, and swelling rear particle diameter is 7.4 ~ 8 mm.
Preferably, in the above method, the chitosan molecule amount is 200 ~ 600kDa, deacetylation 80% ~ 95%；The fine jade
Glue the molecular weight of oligosaccharide is 1000 ~ 3000Da.
Compared with prior art, the present invention has the advantages that：
Content and proportioning, the selection of crosslinking agent by controlling solvent in preparation method of the invention, the shitosan-agar-agar of preparation is low
The porous ball hemostatic material porosity of glycan is big, and swelling effect is excellent, can quickly water absorption and swelling, the closure surface of a wound, blood is facilitated rapidly
It is solidifying, with efficient styptic activity；With certain volume, it is not easily accessible blood and causes thrombotic risk.Meanwhile, the hemostatic material of preparation
Good biocompatibility, safety non-toxic；Possess excellent wound adaptability, be particularly well-suited to deep, narrow and irregular wound hemostasis.
Preparation process is simple of the present invention, it is easy to industrialized production.
Specific embodiment
Explanation is further expalined to the present invention with reference to specific embodiment, its description is more specific and detailed, but
Therefore the limitation to the scope of the claims of the present invention can not be interpreted as, as long as being obtained in the form of equivalent or equivalent transformation
The technical scheme for obtaining, all should be included within the protection domain of the claims in the present invention.
Embodiment 1
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 1%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 200, deacetylation 95%）, prepare 2%（W/V）Shell
Glycan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 2000）, prepare 0.5%（W/V）The agar oligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（2%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）In compound alcohol,
Ultrasound in Ultrasound Instrument is placed in, ultrasonic power is 130W；Above-mentioned shitosan-agar oligosaccharide composite solution is added dropwise with No. 8 syringe needles
To in compound alcohol（Composite solution and compound alcoholic solution volume ratio 1：5）, completion of dropping stopping ultrasound, 600rpm stirrings 30 minutes；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 0.5mm, and porosity is 55%, and swelling rear particle diameter is up to 4.0mm.
Embodiment 2
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 2%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 300, deacetylation 85%）, prepare 2.5%（W/V）
Chitosan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 3000）, prepare 1.0%（W/V）Agar oligosaccharide is water-soluble
Liquid；Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（1.5%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）Compound alcohol
In, ultrasound in Ultrasound Instrument is placed in, ultrasonic power is 135W；By above-mentioned shitosan-agar oligosaccharide composite solution with No. 8 syringe needles
It is added drop-wise in compound alcohol（Composite solution and compound alcoholic solution volume ratio 1：4）, completion of dropping stopping ultrasound, 30 points of 700rpm stirrings
Clock；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 0.9mm, and porosity is 73%, and swelling rear particle diameter is up to 6.2mm.
Embodiment 3
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 2%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 400, deacetylation 90%）, prepare 3%（W/V）Shell
Glycan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 2000）, prepare 1.5%（W/V）The agar oligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（1%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）In compound alcohol,
Ultrasound in Ultrasound Instrument is placed in, ultrasonic power is 140W；Above-mentioned shitosan-agar oligosaccharide composite solution is added dropwise with No. 8 syringe needles
To in compound alcohol（Composite solution and compound alcoholic solution volume ratio 1：5）, completion of dropping stopping ultrasound, 700rpm stirrings 30 minutes；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 1.4mm, and porosity is 90%, and swelling rear particle diameter is up to 8.0mm.
Embodiment 4
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 3%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 600, deacetylation 80%）, prepare 3%（W/V）Shell
Glycan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 1000）, prepare 1.5%（W/V）The agar oligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（0.5%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）Compound alcohol
In, ultrasound in Ultrasound Instrument is placed in, ultrasonic power is 150W；By above-mentioned shitosan-agar oligosaccharide composite solution with No. 8 syringe needles
It is added drop-wise in compound alcohol（Composite solution and compound alcoholic solution volume ratio 1：6）, completion of dropping stopping ultrasound, 30 points of 800rpm stirrings
Clock；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 2.0mm, and porosity is 83%, and swelling rear particle diameter is up to 7.4mm.
Comparative example 1
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 1%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 200, deacetylation 95%）, prepare 2%（W/V）Shell
Glycan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 2000）, prepare 0.5%（W/V）The agar oligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（2%, V/V）It is added to ethanol-isopropanol（Volume ratio 4：6）In compound alcohol, put
The ultrasound in Ultrasound Instrument, ultrasonic power is 130W；Above-mentioned shitosan-agar oligosaccharide composite solution is added drop-wise to No. 8 syringe needles
In compound alcohol（Composite solution and compound alcoholic solution volume ratio 1：5）, completion of dropping stopping ultrasound, 600rpm stirrings 30 minutes；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 0.3 mm, and porosity is 38%, the swelling mm of rear particle diameter 1.1.
Comparative example 2
The preparation method of the porous ball hemostatic material of shitosan-galactooligosaccharide, comprises the following steps：
S1. with 1%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 200, deacetylation 95%）, prepare 2%（W/V）Shell
Glycan solution；Use dissolved in purified water galactooligosaccharide（The Da of molecular weight 2000）, prepare 0.5%（W/V）The galactooligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-galactooligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（2%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）In compound alcohol,
Ultrasound in Ultrasound Instrument is placed in, ultrasonic power is 130W；Above-mentioned shitosan-galactooligosaccharide composite solution is added dropwise with No. 8 syringe needles
To in compound alcohol（Composite solution and compound alcoholic solution volume ratio 1：5）, completion of dropping stopping ultrasound, 600rpm stirrings 30 minutes；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 1.6 mm, and porosity is 35%, the swelling mm of rear particle diameter 6.1.
Comparative example 3
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 1%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 200, deacetylation 95%）, prepare 2%（W/V）Shell
Glycan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 2000）, prepare 0.5%（W/V）The agar oligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by 1,3- diglycidyl ether glycerine（2%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）In compound alcohol,
Magnetic agitation；Above-mentioned shitosan-agar oligosaccharide composite solution is added drop-wise in compound alcohol with No. 8 syringe needles（Composite solution with it is multiple
Close alcoholic solution volume ratio 1：5）, completion of dropping, 600rpm stirrings 30 minutes；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 2.6 mm, and porosity is 31%, and swelling rear particle diameter is up to 4.3 mm.
Comparative example 4
The preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide, comprises the following steps：
S1. with 1%（V/V）Aqueous acetic acid dissolves shitosan（The kDa of molecular weight 200, deacetylation 95%）, prepare 2%（W/V）Shell
Glycan solution；Use dissolved in purified water agar oligosaccharide（The Da of molecular weight 2000）, prepare 0.5%（W/V）The agar oligosaccharide aqueous solution；
Take isometric said two devices solution to mix, shitosan-agar oligosaccharide composite solution is obtained；
S2. by glutaraldehyde（2%, V/V）It is added to isopropanol/isooctanol（Volume ratio 4：6）In compound alcohol, it is placed in Ultrasound Instrument and surpasses
Sound, ultrasonic power is 130W；Above-mentioned shitosan-agar oligosaccharide composite solution is added drop-wise in compound alcohol with No. 8 syringe needles（It is multiple
Close solution and compound alcoholic solution volume ratio 1：5）, completion of dropping stopping ultrasound, 600rpm stirrings 30 minutes；
S3. ball is separated, it is 100% and 50% that concentration is successively used respectively（V/V）Ethanol is washed, -30 DEG C of pre-freezes, and freeze-drying is
Obtain porous ball.
The particle diameter of the hemostatic material drying regime is 0.7 mm, and porosity is 26%, the swelling mm of rear particle diameter 1.9.
External clotting assay：
Blood is taken from new zealand rabbit auricular vein in vacuum test tube（Containing sodium citrate anticoagulant, 3.8% sodium citrate: blood=1
∶9）, it is standby；Clean transparent plastic test tube is taken, the sample in 50mg above-described embodiments and comparative example, jog examination is separately added into
Pipe makes sample try one's best to spread out.Blank cuvette makees negative control, and Yunnan Baiyao powder makees positive control, and setting three test tubes per sample does flat
Row experiment.Successively by the 1 mL above-mentioned test tubes of fresh anti-freezing rabbit blood addition, smoothly move into 37 DEG C of water-baths, start timing；
Every group of test tube is slowly inclined once every 30s（Angle is less than 30 °）, slowly it is inverted untill blood do not flow until test tube,
By second hand stop table, this group of clotting time is write down, the time surpasses 30 minutes and is denoted as " not blood coagulation ", and experimental data is represented with " `x ± s ",
The results are shown in Table 1.
The external clotting assay result of table 1
| Sample | Clotting time（s） |
| Blank | Not blood coagulation |
| Yunnan Baiyao | 255 ±4 |
| Embodiment 1 | 263±6 |
| Embodiment 2 | 236±5 |
| Embodiment 3 | 123±4 |
| Embodiment 4 | 168±5 |
| Comparative example 1 | 471±4 |
| Comparative example 2 | 582±6 |
| Comparative example 3 | 484±3 |
| Comparative example 4 | 522±4 |
As can be seen from Table 1, the porous ball hemostatic material blood coagulation activity of shitosan-agar oligosaccharide that prepared by embodiment 1,2 is high,
It is suitable with Yunnan Baiyao effect, and particle diameter will not enter greatly blood, solve the life that the easy lower tape of the particulate matters such as Yunnan Baiyao comes
Thing potential safety hazard；The porosity of embodiment 3,4 is big, swelling rear particle diameter is big, quick water absorption and swelling, blocks the surface of a wound, and blood is facilitated rapidly
Solidifying, its blood coagulation activity is higher than Yunnan Baiyao, and particle diameter will not enter greatly blood.Be can be seen that by changing this from comparative example 1-4
Invention preparation condition and the material that obtains, its bleeding stopping period are greatly prolonged, and styptic activity is poor.
Claims (5)
1. the preparation method of the porous ball hemostatic material of a kind of shitosan-agar oligosaccharide, it is characterised in that including following step
Suddenly：
S1. 2% ~ 3% is prepared respectively（W/V）Chitosan solution and 0.5% ~ 1.5%（W/V）The agar oligosaccharide aqueous solution, the shell gathers
Sugar juice solvent is 1%-3%（V/V）Aqueous acetic acid；Take isometric chitosan solution and the agar oligosaccharide aqueous solution is mixed, system
Obtain shitosan-agar oligosaccharide composite solution；
S2. it is 4 1,3- diglycidyl ether glycerine to be added into volume ratio:In the compound alcoholic solution of 6 isopropanol/isooctanol, 1,
3- diglycidyl ethers glycerine content in the compound alcoholic solution of isopropanol/isooctanol is 0.5% ~ 2%（V/V）, in ultrasonic power 130
Under conditions of ~ 150W, above-mentioned shitosan-agar oligosaccharide composite solution is added drop-wise to and contains 1,3- diglycidyl ether glycerine
In the compound alcoholic solution of isopropanol/isooctanol, wherein, shitosan-agar oligosaccharide composite solution and contain 1,3- diglycidyls
The volume ratio of the compound alcoholic solution of the isopropanol/isooctanol of ether glycerine is 1:4 ~ 6, completion of dropping stops ultrasound, and 600 ~ 800rpm is stirred
Mix 30 minutes to obtain ball；
S3. the porous ball hemostatic material of shitosan-agar oligosaccharide is obtained final product after filtering out ball through washing, pre-freeze, freeze-drying.
2. the preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide according to claim 1, its feature exists
In washing described in S3 refers to successively to wash ball more than 3 times with the ethanol that volumetric concentration is 100% and 50% respectively.
3. the porous ball hemostatic material of shitosan-agar oligosaccharide that the methods described of claim 1 or 2 is prepared, its feature
It is that the particle diameter of the porous ball hemostatic material drying regime of shitosan-agar oligosaccharide is 0.5 ~ 2 mm, and porosity is
55% ~ 90%, swelling rear particle diameter is 4 ~ 8 mm.
4. the porous ball hemostatic material of shitosan-agar oligosaccharide according to claim 3, it is characterised in that the shell gathers
The particle diameter of the porous ball hemostatic material drying regime of sugar-agar oligosaccharide be 1.4 ~ 2 mm, porosity be 83% ~ 90%, it is swelling after
Particle diameter is 7.4 ~ 8 mm.
5. the preparation method of the porous ball hemostatic material of shitosan-agar oligosaccharide according to claim 1, its feature exists
In the chitosan molecule amount is 200 ~ 600kDa, deacetylation 80% ~ 95%；The agar oligosaccharide molecular weight be 1000 ~
3000Da。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710224056.9A CN106822986B (en) | 2017-04-07 | 2017-04-07 | A kind of preparation method of the porous ball hemostatic material of chitosan-agar oligosaccharide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710224056.9A CN106822986B (en) | 2017-04-07 | 2017-04-07 | A kind of preparation method of the porous ball hemostatic material of chitosan-agar oligosaccharide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822986A true CN106822986A (en) | 2017-06-13 |
| CN106822986B CN106822986B (en) | 2019-11-12 |
Family
ID=59147014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710224056.9A Active CN106822986B (en) | 2017-04-07 | 2017-04-07 | A kind of preparation method of the porous ball hemostatic material of chitosan-agar oligosaccharide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822986B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109942796A (en) * | 2019-03-19 | 2019-06-28 | 广东海洋大学 | One kind is birdsed of the same feather flock together tranxamic acid, preparation method, hemostatic and antibacterial pharmaceutical composition and its application |
| CN113521379A (en) * | 2021-07-12 | 2021-10-22 | 重庆大清海德生物技术有限公司 | Preparation method of large-wound chitosan hemostatic particles |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078302A (en) * | 2010-12-17 | 2011-06-01 | 广东海洋大学 | Method for preparing berbamine chitosan-agar nano particles |
| WO2011151386A1 (en) * | 2010-06-01 | 2011-12-08 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
| WO2013060769A2 (en) * | 2011-10-27 | 2013-05-02 | Baxter International Inc. | Hemostatic compositions |
| CN105920658A (en) * | 2016-04-23 | 2016-09-07 | 厦门凝赋生物科技有限公司 | Porous styptic powder and preparation method thereof |
-
2017
- 2017-04-07 CN CN201710224056.9A patent/CN106822986B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011151386A1 (en) * | 2010-06-01 | 2011-12-08 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
| CN102078302A (en) * | 2010-12-17 | 2011-06-01 | 广东海洋大学 | Method for preparing berbamine chitosan-agar nano particles |
| WO2013060769A2 (en) * | 2011-10-27 | 2013-05-02 | Baxter International Inc. | Hemostatic compositions |
| CN105920658A (en) * | 2016-04-23 | 2016-09-07 | 厦门凝赋生物科技有限公司 | Porous styptic powder and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109942796A (en) * | 2019-03-19 | 2019-06-28 | 广东海洋大学 | One kind is birdsed of the same feather flock together tranxamic acid, preparation method, hemostatic and antibacterial pharmaceutical composition and its application |
| CN109942796B (en) * | 2019-03-19 | 2021-04-06 | 广东海洋大学 | Polystyptic-like cyclic acid, preparation method, hemostatic and antibacterial pharmaceutical composition and application thereof |
| CN113521379A (en) * | 2021-07-12 | 2021-10-22 | 重庆大清海德生物技术有限公司 | Preparation method of large-wound chitosan hemostatic particles |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822986B (en) | 2019-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wei et al. | Polysaccharides-modified chitosan as improved and rapid hemostasis foam sponges | |
| Wang et al. | Preparation and evaluation of chitosan/alginate porous microspheres/Bletilla striata polysaccharide composite hemostatic sponges | |
| CN102139123B (en) | Method for preparing intra-operative hemostatic material by cross emulsification of plant starch | |
| CN102406956B (en) | Starch hemostatic microsphere and preparation method thereof | |
| Zhang et al. | Application status and technical analysis of chitosan-based medical dressings: A review | |
| CN110522945B (en) | Medical biogel hemostatic dressing and preparation method thereof | |
| CN106620824A (en) | Preparation method for efficient anti-bacterial composite hemostatic sponge | |
| CN105597144A (en) | Absorbable collagen styptic powder and preparing method thereof | |
| Zheng et al. | A novel pullulan oxidation approach to preparing a shape memory sponge with rapid reaction capability for massive hemorrhage | |
| CN103848926B (en) | A kind of preparation method of using carboxyl chitosan and purposes | |
| CN101695581A (en) | Method for preparing human-like collagen haemostatic sponge in scale | |
| CN105688265A (en) | Absorbable hemostatic material as well as preparation method and use thereof | |
| CN103055343B (en) | Potato starch-hyaluronic acid composite hemostatic powder and preparation method thereof | |
| CN106822987B (en) | A kind of preparation method of the porous ball hemostatic material of chitin-alginic acid salt | |
| CN107412843B (en) | Starch-based microporous hemostatic material with antibacterial property and preparation method and application thereof | |
| CN107501579B (en) | Chitosan hemostatic material formed by covalent crosslinking and preparation method thereof | |
| CN105126152B (en) | A kind of gelatin chitosan compound hemostatic powder | |
| CN110124082A (en) | Swelling type medical bio gel filler based on Polysaccharide from Portulaca oleracea and chromocor extract | |
| CN106822986B (en) | A kind of preparation method of the porous ball hemostatic material of chitosan-agar oligosaccharide | |
| CN104208741A (en) | Chitosan based adhesive bandage | |
| Zhou et al. | Preparation and application of hemostatic hydrogels | |
| CN103550815A (en) | Preparation method of microporous polysaccharide microspheres | |
| CN103933601B (en) | A kind of shitosan compound hemostatic powder and preparation method thereof | |
| CN107029280B (en) | A kind of preparation method of chitin-alginic acid salt soft capsule grain hemostatic material | |
| CN105233326A (en) | Preparation method and preparation of absorbable micropore vacuum polysaccharide particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |